Tolvaptan
- Generic Name
- Tolvaptan
- Brand Names
- Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25ClN2O3
- CAS Number
- 150683-30-0
- Unique Ingredient Identifier
- 1E2497LPNY
- Background
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
- Indication
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
- Associated Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06698822
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06689982
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
- Conditions
- Blau Syndrome
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06688838
- Locations
- 🇨🇳
Yikai YU, Wuhan, Hubei, China
JAK Inhibitor Dose TAPering Strategy Study
- Conditions
- Rhumatoid Arthisis
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 308
- Registration Number
- NCT06687551
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
- Conditions
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Drug: TNFi (Tumor Necrosis Factor inhibitor) medication
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Duke University
- Target Recruit Count
- 400
- Registration Number
- NCT06654882
TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 75
- Registration Number
- NCT06625450
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
- Conditions
- Janus Kinase InhibitorsAlopecia Areata
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 150
- Registration Number
- NCT06573593
- Locations
- 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
- Conditions
- Heart Failure With Volume Overload
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06506994
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
- Conditions
- Takayasu Arteritis
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06498089
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
- Conditions
- Toxic Epidermal NecrolysisStevens-Johnson Syndrome
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06474078
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.